India’s pharma exports surpass USD 30 Billion in FY2025 and aim to double by 2030: Rubix Data Sciences

New Delhi: As trade realignments and tariff tensions redefine global pharma supply chains, India is emerging as a resilient force. With exports touching USD 30.5 billion in FY2025, a 9.3% jump from the previous year, the country is laying the foundation to double its pharmaceutical exports by 2030.

In this fast-shifting landscape, Rubix Data Sciences, a leading provider of risk management and monitoring solutions, has released its latest industry report on India’s pharmaceutical sector. The report captures how Indian pharma players are navigating uncertainty by doubling down on complex generics, expanding their international presence, and investing in regulatory strength.

India’s strength comes at a time of rising external volatility. The United States, which alone accounts for over 32% of India’s pharmaceutical exports, is reportedly considering a 200% tariff on pharmaceutical imports. These potential trade shifts carry real implications for India, whose pharma exports are projected to double to USD 65 billion by 2030. But India is not standing still. From strategic acquisitions by Indian CDMOs (Contract Development and Manufacturing Organizations) in the US and Europe to the increasing share of complex generics in their product mix, Indian companies are proactively mitigating these risks. The Rubix report highlights how Indian pharma companies are responding proactively by investing in US-facing manufacturing capabilities, expanding regulatory compliance, and targeting complex generics aligned with upcoming patent expiries. As global pharmaceutical markets brace for a series of high-value drug patent expiries over the next five years, Indian companies are sharpening their focus on complex generics and differentiated products.

The Rubix report further points to a clear shift in strategic priorities among Indian pharma firms, particularly as global risks mount. Companies are enhancing their competitiveness by entering advanced therapeutic areas like oncology, anti-diabetics, and CNS. Many firms are also scaling up their international footprint through partnerships and acquisitions, especially in developed markets, to strengthen supply continuity and regulatory compliance. With 74% of bulk drug imports still coming from China, the push toward diversification both in sourcing and in global customer bases has become a critical lever for long-term resilience.

“The surge in pharma exports this year is encouraging, but it also reflects how Indian manufacturers are recalibrating in response to global uncertainties. From navigating tariff pressures to strengthening regulatory compliance and expanding globally, the sector is showing clear signs of strategic maturity. We believe this momentum will continue as companies focus more on complex generics and strengthen their specialised capabilities. At Rubix, our focus remains on equipping stakeholders with data-driven insights that enable smarter, risk-aware decisions in a rapidly evolving global market,” said Mohan Ramaswamy, Co-founder and CEO, Rubix Data Sciences.

At a time when global supply chains are increasingly politicised and access to affordable medicines is under threat from protectionist measures, the insights from this report are both timely and critical. As the August 1 tariff deadline approaches, the choices made by Indian policymakers and businesses could reshape not just India’s trajectory, but the health of millions worldwide who depend on its medicines. The Rubix Industry Insights report offers real-time intelligence to help stakeholders navigate complexity, spot opportunity, and build long-term resilience.